Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Deborah L. White, PhD. FFSc(RCPA), Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Cassandra Slader, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P Hughes, MD, MBBS

Blood (2011) 118 (21): 1690.

https://doi.org/10.1182/blood.V118.21.1690.1690

Published: 2011

Journal Articles

Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,

Jueqiong Wang, MMed, Timothy P Hughes, MD, MBBS, Chung Hoow Kok, PhD, Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Michael Philip Osborn, MBBS, Andrew A Somogyi, PhD, Richard J D'Andrea, PhD, Deborah L. White, PhD. FFSc(RCPA)

Blood (2011) 118 (21): 3501.

https://doi.org/10.1182/blood.V118.21.3501.3501

Published: 2011

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Jane R. Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, Timothy P. Hughes

Blood (2010) 116 (15): 2776–2778.

https://doi.org/10.1182/blood-2010-01-267013

Published: 2010

Journal Articles

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Devendra K Hiwase, MD, Deborah L White, PhD, Jason A Powell, PhD, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, PhD, L. Bik To, MD, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 3250.

https://doi.org/10.1182/blood.V114.22.3250.3250

Published: 2009

Journal Articles

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Deborah L White, PhD, Verity A Saunders, Amity Frede, Phuong Dang, Stephanie Zrim, Michael Philip Osborn, MB, BS, Paul Manley, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 507.

https://doi.org/10.1182/blood.V114.22.507.507

Published: 2009

Journal Articles

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Jane R Engler, Amity Frede, Verity A Saunders, Andrew Christopher William Zannettino, BSc, PhD, Deborah L White, Timothy P. Hughes, MD

Blood (2009) 114 (22): 2189.

https://doi.org/10.1182/blood.V114.22.2189.2189

Published: 2009

Journal Articles

Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients

Deborah White, PhD, Phuong Dang, Kelvin Groot Obbink, Amity Frede, Chung Kok, Timothy P Hughes, MD, Richard D’Andrea, PhD

Blood (2008) 112 (11): 723.

https://doi.org/10.1182/blood.V112.11.723.723

Published: 2008

Journal Articles

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler, Amity Frede, Andrew C W Zannettino, PhD, Deborah L White, PhD, Timothy P Hughes, MD

Blood (2008) 112 (11): 196.

https://doi.org/10.1182/blood.V112.11.196.196

Published: 2008

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

NARROW

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only